摘要
目的探讨唑来膦酸联合参丹散结胶囊治疗肺癌患者的临床疗效。方法选取2013年3月至2014年5月吉林省肿瘤医院收治的肺癌患者资料68例,按随机数字表法分为对照组和观察组,每组34例。观察组患者给予唑来膦酸联合参丹散结胶囊治疗,对照组患者给予唑来膦酸治疗,比较两组患者的临床疗效及不良反应情况。结果观察组患者总有效率为94.1%,不良反应发生率为8.8%;对照组患者总有效率为70.6%,不良反应发生率为26.5%。观察组患者总有效率高于对照组,不良反应发生率低于对照组,差异有统计意义(P<0.05)。结论唑来膦酸联合参丹散结胶囊治疗肺癌患者起效迅速、安全,不良反应轻微。
Objective To value of combined application of the treatment of lung cancer with the medicinal powder and the Unite.Methods From May 2014 to March 2013,68 cases of lung cancer patients were randomly divided into control group and observation group,34 cases in each group.The observation group was treated with the combination of the two groups.The patients in the control group were treated with the treatment of the disease.The clinical efficacy and adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 94.1%,the adverse reaction rate was 8.8%,the total effective rate was 70.6% in the control group, the adverse reaction rate was 26.5%. The total effective rate of the observation group was higher than that of the control group, the incidence of adverse reaction was lower than that of the control group,the difference between the two groups（P〈0.05）.Conclusion The treatment of lung cancer with the combination of the effects of the combination of the treatment of the combination of the combination of the drug and the combination of the.
出处
《中国药物经济学》
2016年第4期90-92,共3页
China Journal of Pharmaceutical Economics
关键词
肺癌
唑来膦酸
参丹散结胶囊
临床疗效
Lung cancer
The acid
The capsule of the capsule
Curative effect
